Verteporfin

Known as: BPD verteporfin, Verteporfinum, BPD-MA 
A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and… (More)

Topic mentions per year

Topic mentions per year

1981-2017
05010019812017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
PURPOSE To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of… (More)
  • table 3
  • figure 1
  • table 5
  • table 7
  • table 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE To evaluate the efficacy and safety of triple therapy with verteporfin photodynamic therapy (PDT), dexamethasone, and… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of… (More)
  • table 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE To investigate the safety and efficacy of intravitreal ranibizumab treatment combined with verteporfin photodynamic… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with… (More)
Is this relevant?
2002
2002
We evaluated, in a nonrandomised, institutional, prospective study, the efficacy of photodynamic therapy (PDT) with verteporfin… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
OBJECTIVE To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with… (More)
  • table 2
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
DECLINING ESTROGEN LEVELS at menopause result in increased bone turnover and a loss of bone mass, with subsequent increases in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?